April 17 (Reuters) - DelMar Pharmaceuticals Inc:
* DELMAR PHARMACEUTICALS PRESENTS POSITIVE UPDATES ON TWO ONGOING CLINICAL TRIALS WITH VAL-083 FOR TREATMENT OF MGMT-UNMETHYLATED GBM
* DELMAR PHARMACEUTICALS - NO DOSE-LIMITING TOXICITIES HAVE BEEN REPORTED FOLLOWING TREATMENT WITH MULTIPLE CYCLES OF VAL-083 Source text for Eikon: Further company coverage: